Voyager Therapeutics (NASDAQ:VYGR) CEO Sells $53,806.63 in Stock

Voyager Therapeutics, Inc. (NASDAQ:VYGR) CEO Alfred Sandrock sold 14,197 shares of the firm’s stock in a transaction dated Tuesday, February 24th. The shares were sold at an average price of $3.79, for a total transaction of $53,806.63. Following the transaction, the chief executive officer directly owned 484,060 shares in the company, valued at $1,834,587.40. The trade was a 2.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Alfred Sandrock also recently made the following trade(s):

• On Tuesday, February 10th, Alfred Sandrock sold 12,192 shares of Voyager Therapeutics stock. The stock was sold at an average price of $3.78, for a total value of $46,085.76.

Voyager Therapeutics Stock Performance

NASDAQ:VYGR traded up $0.04 during trading on Thursday, reaching $4.13. The company’s stock had a trading volume of 151,278 shares, compared to its average volume of 584,842. Voyager Therapeutics, Inc. has a 12 month low of $2.64 and a 12 month high of $5.55. The firm has a market cap of $229.63 million, a price-to-earnings ratio of -1.91 and a beta of 1.30. The firm has a 50 day moving average of $3.86 and a 200-day moving average of $4.11.

Analysts Set New Price Targets

A number of research analysts have recently commented on VYGR shares. Wedbush reaffirmed an “outperform” rating and set a $8.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, November 11th. HC Wainwright decreased their price target on Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, November 12th. Finally, Wall Street Zen lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Voyager Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $13.75.

Hedge Funds Weigh In On Voyager Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Invesco Ltd. lifted its holdings in shares of Voyager Therapeutics by 28.2% during the 4th quarter. Invesco Ltd. now owns 116,000 shares of the company’s stock worth $456,000 after acquiring an additional 25,522 shares during the last quarter. Sphera Funds Management LTD. lifted its stake in Voyager Therapeutics by 70.1% during the fourth quarter. Sphera Funds Management LTD. now owns 339,761 shares of the company’s stock worth $1,335,000 after purchasing an additional 140,000 shares during the last quarter. Quadrature Capital Ltd bought a new stake in Voyager Therapeutics during the fourth quarter worth about $120,000. Opaleye Management Inc. bought a new position in shares of Voyager Therapeutics during the 4th quarter valued at about $4,704,000. Finally, EcoR1 Capital LLC increased its position in shares of Voyager Therapeutics by 497.2% during the 4th quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company’s stock valued at $15,731,000 after purchasing an additional 3,332,544 shares during the last quarter. Hedge funds and other institutional investors own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.